Novartis Gets CDSCO Panel Nod To Study Antiparasitic drug LXE408

Written By : Dr. Divya Colin |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2025-03-07T17:15:30+05:30 | Updated On 7 March 2025 5:15 PM IST

Novartis receives USFDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy

New Delhi: Drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the clinical study of the antiparasitic drug LXE408.

The firm presented phase 1 clinical study protocol no.: CLXE408A12105 amendment version no. 1 dated 31-January- 2025.

LXE408 is a first-in-class parasite-selective inhibitor of the kinetoplastid proteasome with potent and uniform anti-parasitic activity against all kinetoplastid parasites, including Leishmania species causing visceral leishmaniasis (L. donovani and L. infantum), as well as parasites causing Chagas disease (T. cruzi) and human African trypanosomiasis (T. brucei).

At the recent SEC meeting for antimicrobials and antivirals held on 13th and 14th February 2025, the expert panel reviewed the phase 1 clinical study protocol no.: CLXE408A12105amendment version no. 1 dated 31-January- 2025.

After detailed deliberation, the committee recommended the grant of permission to conduct the trial as presented by the firm.

Also Read: Alkem Laboratories Gets CDSCO Panel Nod To Study Semaglutide solution for injection

LXE408novartiscdscoantiparasitic drug

Dr. Divya Colin

Doctor of Pharmacy

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751